MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jacc.2019.10.032

Медицинская библиотека · Journal of the American College of Cardiology · 2019

Quality Assurance for Carotid Stenting in the CREST-2 Registry.

Lal Brajesh K, Roubin Gary S, Rosenfield Kenneth, Heck Donald, Jones Michael, Jankowitz Brian, Jovin Tudor, Chaturvedi Seemant, Dabus Guilherme, White Christopher J, Gray William, Matsumura Jon, Katzen Barry T, Hopkins L Nelson, Mayorga-Carlin Minerva, Sorkin John D, Howard George, Meschia James F, Brott Thomas G

СтатьяМногоцентровое исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

The CREST-2 Registry (C2R) was approved by National Institute of Neurological Disorders and Stroke-National Institutes of Health in September 2014 with Centers for Medicare & Medicaid Services, U.S. Food and Drug Administration, and industry collaboration to enroll patients undergoing CAS. The registry credentials interventionists and promotes optimal patient selection, procedural-technique, and outcomes.

OBJECTIVES

This study reports periprocedural outcomes in a cohort of carotid artery stenting (CAS) performed for asymptomatic and symptomatic carotid stenosis.

METHODS

Asymptomatic patients with ≥70% and symptomatic patients with ≥50% carotid stenosis, ≤80 years of age, and at standard or high risk for carotid endarterectomy are eligible for enrollment. Interventionists are credentialed by a multispecialty committee that reviews experience, lesion selection, technique, and outcomes. The primary endpoint was a composite of stroke and death (S/D) in the 30-day periprocedural period. Myocardial infarction and access-site complications were assessed as secondary outcomes.

RESULTS

As of December 2018, 187 interventionists from 98 sites in the United States performed 2,219 CAS procedures in 2,141 patients with primary atherosclerosis (78 were bilateral). The mean age of the cohort was 68 years, 65% were male, and 92% were white; 1,180 (55%) were for asymptomatic disease, and 961 (45%) were for symptomatic disease. All U.S. Food and Drug Administration-approved stents and embolic protection devices were represented. The 30-day rate of S/D was 1.4% for asymptomatic, 2.8% for symptomatic, and 2.0% for all patients.

CONCLUSIONS

C2R is the first national registry for CAS cosponsored by federal and industry partners. CAS was performed by experienced operators using appropriate patient selection and optimal technique. In that setting, a broad group of interventionists achieved very low periprocedural S/D rates for asymptomatic and symptomatic patients.

Для цитирования: Lal Brajesh K, Roubin Gary S, Rosenfield Kenneth, Heck Donald, Jones Michael, Jankowitz Brian, Jovin Tudor, Chaturvedi Seemant, Dabus Guilherme, White Christopher J, Gray William, Matsumura Jon, Katzen Barry T, Hopkins L Nelson, Mayorga-Carlin Minerva, Sorkin John D, Howard George, Meschia James F, Brott Thomas G. Quality Assurance for Carotid Stenting in the CREST-2 Registry.. Journal of the American College of Cardiology. 2019. DOI: 10.1016/j.jacc.2019.10.032.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.